Previous 10 | Next 10 |
AlloVir press release ( NASDAQ: ALVR ): FY GAAP EPS of -$2.20 beats by $0.05 . As of December 31, 2022, AlloVir had cash, cash equivalents, and marketable securities of $233.8 million, compared with cash, cash equivalents, and marketable securities of $248.1 million as of Dece...
Completion of enrollment of all three posoleucel Phase 3 registrational trials for three distinct, first-to-market indications anticipated by end of 2023 and data readouts in 2024 Positive final results from randomized, double-blind, placebo-controlled Phase 2 study of posoleucel in kidne...
Repeat administration of posoleucel was generally well tolerated, with balanced safety across posoleucel dosing groups and placebo In Week 24 efficacy analysis, 39% (15/38) of patients who received posoleucel experienced a ≥1-log viral load reduction, more than double the placebo r...
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced that Chief Executive Officer Diana Brainard, M.D., will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 10:00 a.m. ET. ...
Positive final posoleucel Phase 2 clinical data presented at ASH 2022 underscore potential as multi-virus prevention therapy and support ongoing global Phase 3 registration trial Completion of enrollment of all three posoleucel Phase 3 registrational trials anticipated by the end of 2...
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023, at 2:15 p.m. PST. A...
23 of 26 (88%) patients remained free of clinically significant infections caused by any of six common viruses that posoleucel targets through the Week 14 primary endpoint 3 of 26 (12%) patients had clinically significant infections despite 22 of 26 (85%) patients reactivating one or more...
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference in New York on Tuesday, November 29...
Summary AlloVir, Inc. has some solid data in an area of unmet need. AlloVir is well-capitalized to complete its trials. However, the market doesn't seem interested at present. AlloVir , Inc. ( ALVR ) is a leader in the development of allogeneic, virus-specifi...
AlloVir press release ( NASDAQ: ALVR ): Q3 GAAP EPS of -$0.50 beats by $0.03 . As of September 30, 2022, AlloVir had cash, cash equivalents, and marketable securities of $264.1 million, compared with $248.1 million as of December 31, 2021. For further details see...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...